News and features
Read the latest news and features about our world-leading research, discoveries, fundraising and philanthropy. If you want to keep updated on our news, you can follow us on social media or sign up for our Search newsletter.
If you’re a journalist and want to find out more, you can contact our media relations team.
AI twice as accurate as a biopsy at grading aggressiveness of some sarcomas
Artificial intelligence (AI) could be around twice as accurate as a biopsy at grading the aggressiveness of some sarcomas, according to new research from The Royal Marsden NHS Foundation Trust and The Institute of Cancer Research, London.
High-performance computing facilitates new radiotherapy approach that could improve therapy for hard-to-treat cancers
Researchers have used methods from high-performance computing to significantly reduce the time it takes to reconstruct images acquired through four-dimensional magnetic resonance imaging (4D-MRI).
ICR amongst top UK universities for industry and academic partnerships and public engagement
The ICR has ranked as one of the UK's best higher education institutions at engaging with industry, academic partners and the wider public, in the Government's latest Knowledge Exchange Framework (KEF).
New clinical trial guidelines set to increase transparency and support progress in developing new therapies
New guidelines have been developed to help researchers ensure that their clinical trial protocols and reports are complete, high-quality and transparent.
Scientists reverse drug resistance in prostate cancer by targeting 'hijacked' white blood cells
Prostate cancer’s resistance to treatment can be reversed in some patients by stopping hijacked white blood cells from being ‘pulled into’ tumours, according to new research published in Nature.
-without-tumour-550x410.jpg?sfvrsn=acf3746f_2 "brown-mouse-(vtelaml1)-without-tumour 550x410")
ICR one of founding institutions of new childhood cancer non-profit company
The Institute of Cancer Research is one of the founding members of a new not-for-profit company that will enable scientists across the world to test cancer drugs in cell and animal models of childhood cancers.
Scientists uncover key mechanism linking DNA replication to cancer
Researchers have gained a clearer insight into how common alterations to the structure of DNA affect the process of DNA replication.
-being-attacked-by-two-cytotoxic-t-cells-(red)-547x410.tmb-hbmobile.png?Culture=en&sfvrsn=8f59440b_2 "Immunotherapy - Oral squamous cancer cell (white) being attacked by two cytotoxic T cells (red) 547x410")
Immunotherapy shows promise as a kinder first-line treatment for advanced head and neck cancers
Immunotherapy can extend the response of some head and neck tumours to treatment, maintaining the anti-tumour effects and preventing them from growing or spreading for longer, a study reports.
Stage set for major new life-sciences redevelopment at The London Cancer Hub
The ICR has welcomed the news that insurer Aviva and developer Socius have been announced as the preferred bidder for a major life-sciences redevelopment project at The London Cancer Hub in Sutton.
Scientists identify 11 new genes linked to aggressive prostate cancer
Researchers have identified 11 new gene alterations that are linked to more aggressive prostate cancer which can be picked up with a simple blood test.
New MedTech firm expands liquid biopsy research at The London Cancer Hub’s Innovation Gateway
Vortex Biosciences is expanding its footprint at The London Cancer Hub’s Innovation Gateway in support of its next phase of growth, having opened a new laboratory there earlier this year.
Higher doses of radiotherapy cut treatment time by up to 75 per cent in localised prostate cancer patients, while maintaining high cure rates
People with low to medium-risk, localised prostate cancer can be treated as effectively using fewer and higher doses of radiation therapy delivered over five treatment sessions as they can with lower doses delivered over several weeks, according to researchers from The Royal Marsden NHS Foundation Trust and The Institute of Cancer Research, London.
